Articles tagged "Adverse effects"

2016 American Transplant Congress
Predictive Model for Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, SC.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to create a model to…
2016 American Transplant Congress
Evaluation of the Toxicity Profile of Proteasome Inhibitor-Based Therapy for Antibody Mediated Rejection.
A. Leino,¹ A. Lichvar,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,¹ F. Paterno,¹ R. Alloway,¹ A. Shields,^1,2 E. Woodle.¹
¹U of Cinncinati, Cincinnati; ²The Christ Hospital, Cincinnati.
Background: Experience with bortezomib (BTZ) antibody mediated rejection (AMR) therapy has progressively increased over the past few years. The BTZ toxicity profile in the transplant…
2016 American Transplant Congress
Pharmacist Impact on Medication Errors in a Chronic Kidney Transplant Clinic.
K. Covert,¹ C. Mardis,¹ J. Fleming,¹ A. Mardis,¹ H. Meadows,¹ N. Pilch,¹ P. Mohan,² M. Posadas,² M. Salazar,² T. Srinivas,² G. Mour,² D. Taber.¹
¹Pharmacy, The Medical University of South Carolina, Charleston, SC; ²Transplant Nephrology, The Medical University of South Carolina, Charleston, South Carolina.
Medication errors are associated with increased incidence of infection, rejection, and graft loss in kidney transplant recipients. This study aims to assess the impact of…
2016 American Transplant Congress
Simulating Alternative Bayesian Criteria to Identify Transplant Center Performance Outliers.
J. Schold,¹ C. Miller,¹ M. Henry,² L. Buccini,¹ S. Flechner,¹ D. Goldfarb,¹ E. Poggio,¹ K. Andreoni.³
¹Cleveland Clinic, Cleveland, OH; ²Ohio State University, Columbus, OH; ³University of Florida, Gainesville, FL.
The newly constructed Bayesian models to evaluate transplant center performance were implemented in 2014. The rates and impact of the assumptions used for flagging centers…
2016 American Transplant Congress
High-Risk Pharmacogenetic (PGx) Variants in Kidney Transplant (tx) Recipients.
D. Berglund,¹ D. Schladt,² K. Sanghavi,¹ W. Guan,¹ B. Wu,¹ C. Dorr,³ R. Remmel,¹ R. Mannon,⁴ A. Matas,¹ W. Oetting,¹ A. Israni,³ P. Jacobson,¹ DeKAF Genomics Investigators.
¹UofMN, Mpls; ²MMRF, Mpls; ³HCMC, Mpls; ⁴UAB, Birmingham.
Kidney tx recipients carry a high burden of comorbidities, and some of the medications for these conditions have genetic predictors of efficacy and toxicity. These…
2015 American Transplant Congress
Clinically Relevant Wound Events With Everolimus-Based Immunosuppressive Regimen: Post-Hoc Analysis from a Randomized Heart Transplant Study
A. Zuckermann,¹ M. Rinaldi,¹ N. Yonan,¹ S.-S. Wang,¹ G. Dong,² P. Lopez.²
¹For the A2309 Study Group, Vienna, Austria; ²Novartis, Basel, Switzerland.
Purpose: In the A2310 (NCT00300274) heart transplant (HTx) study with everolimus (EVR) vs mycophenolate mofetil (MMF), information on a broad spectrum of potential wound healing…
2015 American Transplant Congress
Alemtuzumab Induction Has Been Safe in the United Kingdom and Achieves Long-Term Steroid Avoidance in More Than 80% of Low Risk Renal Transplant Recipients
A. Seitz,¹ M. Robb,³ S. Balasubramanian,¹ A. McLean,² D. Taube,² R. Johnson,³ R. Baker.¹
¹Renal Unit, St. James's Hospital, Leeds, United Kingdom; ²West London Renal and Transplant, Hammersmith Hospital, London, United Kingdom; ³Organ Donation and Transplantation Studies, NHS Blood and Transplant, Bristol, United Kingdom.
Introduction: The use of alemtuzumab as an induction agent for renal transplantation is increasing in the UK. There is some evidence to suggest that this…
2015 American Transplant Congress
Associations of Pre-Transplant Prescription Narcotic Use With Clinical Complications After Kidney Transplantation
N. Lam,¹ M. Schnitzler,² J. Tuttle-Newhall,² H. Xiao,² D. Axelrod,³ D. Brennan,⁴ V. Dharnidharka,⁴ M. Nazzal,² K. Lentine.²
¹Western University, London, ON, Canada; ²Saint Louis University, St. Louis, MO; ³Dartmouth Hitchcock Medical Center, Hanover, NH; ⁴Washington University School of Medicine, St. Louis, MO.
Background: Associations of narcotic use before kidney transplantation with post-transplant clinical outcomes are not well described.Methods: We performed a retrospective analysis of linked national registry…
2015 American Transplant Congress
Adverse Events of Maintenance Immunosuppression Following Kidney Transplantation Reported in Randomized Controlled Trials: A Systematic Review
M. Howell,^1,2 R. Yeo,² A. Tong,^1,2 J. Craig,^1,2 K. Howard,² G. Wong.^2,3
¹Centre for Kidney Research, The Children's Hospital at Westmead, Westmeand, NSW, Australia; ²School of Public Health, University of Sydney, Sydney, NSW, Australia; ³Centre for Transplant and Renal Research, Westmead Hospital, Westmead, NSW, Australia.
Aim: To evaluate the completeness of reporting of adverse events in randomized controlled trials (RCTs) of maintenance immunosuppression in kidney transplantation.Background: Side effects of maintenance…
2015 American Transplant Congress
Quality of Life, Financial, and Mental Health Outcomes for Individuals Turned Down for Live Kidney Donation
P. Reese,¹ C. Carney,¹ S. Levsky,¹ R. Pendse,¹ D. Leidy,¹ A. Mussell,¹ R. Bloom,¹ M. Allen,¹ D. Collins,¹ S. Keddem,¹ P. Abt,¹ J. Rodrigue,² E. Emanuel.¹
¹UPenn, Philadelphia, PA; ²Harvard, Cambridge, MA.
Introduction: Individuals considering live kidney donation should have a thorough understanding of the risks and benefits. Regulations focus exclusively on donation risks. However, no data…